Editas Medicine Inc
Company Profile
Business description
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Contact
11 Hurley Street
CambridgeMA02141
USAT: +1 617 401-9000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
226
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,831.50 | 53.60 | 0.61% |
| CAC 40 | 7,878.46 | 111.75 | 1.44% |
| DAX 40 | 24,549.56 | 342.65 | 1.42% |
| Dow JONES (US) | 44,458.30 | 217.54 | 0.49% |
| FTSE 100 | 8,867.02 | 12.84 | 0.15% |
| HKSE | 23,914.79 | 22.47 | 0.09% |
| NASDAQ | 20,611.34 | 192.87 | 0.94% |
| Nikkei 225 | 39,616.80 | 204.48 | -0.51% |
| NZX 50 Index | 12,736.69 | 31.92 | -0.25% |
| S&P 500 | 6,263.26 | 37.74 | 0.61% |
| S&P/ASX 200 | 8,593.70 | 55.10 | 0.65% |
| SSE Composite Index | 3,505.58 | 12.53 | 0.36% |